Payment overview · 2025
General Payments
$809.39
38 reported records · 11 companies
Healthcare provider profile · identity verified
Beverly Encarnacion, MD
Allopathic & Osteopathic Physicians|Internal Medicine · DUNEDIN, FL · NPI 1659331270
Verified facts
What the public records show
CMS Open Payments records show Beverly Encarnacion, MD received $809.39 in general payments during 2025 across 38 reported records.
GlaxoSmithKline, LLC. accounted for 18.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Ozempic, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 137 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $145.43 | 18.0% | 6 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $142.59 | 17.6% | 8 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $115.29 | 14.2% | 5 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $89.52 | 11.1% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $88.71 | 11.0% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $71.77 | 8.9% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $41.48 | 5.1% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $40.94 | 5.1% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $32.08 | 4.0% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $26.11 | 3.2% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $15.47 | 1.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $809.39 | 38 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $135.96 | 5 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $97.70 | 4 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $89.52 | 5 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $78.73 | 5 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $71.77 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $63.86 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $41.48 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $41.48 | 2 | 2025 |
Source payment records
|
|||||
| WATCHMAN Access System Normalized: watchman access system |
Device | Boston Scientific Corporation | $32.08 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $26.11 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $24.01 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $24.00 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $21.60 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $21.60 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $19.34 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $17.59 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $15.47 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $9.47 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 137 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 74 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 40 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 58 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
58 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
74 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
40 | 12 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
137 | 33 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 790 | 262 |
| Levothyroxine Sodium | Levothyroxine Sodium | 600 | 171 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 595 | 211 |
| Amlodipine Besylate | Amlodipine Besylate | 538 | 193 |
| Losartan Potassium | Losartan Potassium | 515 | 172 |
| Alprazolam | Alprazolam | 470 | 92 |
| Lisinopril | Lisinopril | 462 | 160 |
| Gabapentin | Gabapentin | 435 | 149 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 303 | 54 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 279 | 97 |
| Metformin Hcl | Metformin Hcl | 276 | 101 |
| Metoprolol Tartrate | Metoprolol Tartrate | 246 | 91 |
| Omeprazole | Omeprazole | 243 | 82 |
| Trazodone Hcl | Trazodone Hcl | 227 | 79 |
| Pantoprazole Sodium | Pantoprazole Sodium | 203 | 82 |
| Tramadol Hcl | Tramadol Hcl | 197 | 61 |
| Baclofen | Baclofen | 192 | 82 |
| Simvastatin | Simvastatin | 185 | 58 |
| Furosemide | Furosemide | 183 | 76 |
| Zolpidem Tartrate | Zolpidem Tartrate | 181 | 28 |
| Escitalopram Oxalate | Escitalopram Oxalate | 172 | 64 |
| Celecoxib | Celecoxib | 170 | 66 |
| Metoprolol Succinate | Metoprolol Succinate | 170 | 57 |
| Clopidogrel | Clopidogrel Bisulfate | 156 | 50 |
| Prednisone | Prednisone | 154 | 61 |
| Donepezil Hcl | Donepezil Hcl | 149 | 52 |
| Pravastatin Sodium | Pravastatin Sodium | 146 | 49 |
| Ibuprofen | Ibuprofen | 142 | 61 |
| Eliquis | Apixaban | 137 | 33 |
| Memantine Hcl | Memantine Hcl | 129 | 35 |
| Montelukast Sodium | Montelukast Sodium | 123 | 41 |
| Lorazepam | Lorazepam | 114 | 22 |
| Sertraline Hcl | Sertraline Hcl | 112 | 40 |
| Glimepiride | Glimepiride | 110 | 40 |
| Carvedilol | Carvedilol | 109 | 39 |
| Tamsulosin Hcl | Tamsulosin Hcl | 109 | 43 |
| Alendronate Sodium | Alendronate Sodium | 108 | 42 |
| Spironolactone | Spironolactone | 106 | 40 |
| Hydrochlorothiazide | Hydrochlorothiazide | 105 | 39 |
| Duloxetine Hcl | Duloxetine Hcl | 101 | 32 |
| Potassium Chloride | Potassium Chloride | 100 | 35 |
| Ezetimibe | Ezetimibe | 98 | 35 |
| Famotidine | Famotidine | 93 | 31 |
| Fluticasone Propionate | Fluticasone Propionate | 92 | 37 |
| Meloxicam | Meloxicam | 91 | 41 |
| Hydralazine Hcl | Hydralazine Hcl | 90 | 31 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 87 | 69 |
| Oxybutynin Chloride | Oxybutynin Chloride | 86 | 19 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 81 | 23 |
| Pioglitazone Hcl | Pioglitazone Hcl | 81 | 25 |
| Xarelto | Rivaroxaban | 78 | 13 |
| Allopurinol | Allopurinol | 76 | 25 |
| Jardiance | Empagliflozin | 74 | 23 |
| Buspirone Hcl | Buspirone Hcl | 73 | 32 |
| Ibandronate Sodium | Ibandronate Sodium | 70 | 26 |
| Warfarin Sodium | Warfarin Sodium | 70 | 16 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 69 | suppressed |
| Bumetanide | Bumetanide | 67 | 25 |
| Clonazepam | Clonazepam | 67 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 64 | 57 |
| Fluoxetine Hcl | Fluoxetine Hcl | 64 | 21 |
| Ropinirole Hcl | Ropinirole Hcl | 62 | 18 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 58 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 56 | 21 |
| Clonidine Hcl | Clonidine Hcl | 55 | 23 |
| Valsartan | Valsartan | 55 | 21 |
| Azithromycin | Azithromycin | 53 | 48 |
| Quetiapine Fumarate | Quetiapine Fumarate | 53 | 16 |
| Atenolol | Atenolol | 52 | 18 |
| Paroxetine Hcl | Paroxetine Hcl | 52 | 16 |
| Tizanidine Hcl | Tizanidine Hcl | 51 | 15 |
| Mirtazapine | Mirtazapine | 50 | 15 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 48 | 27 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 46 | 14 |
| Nortriptyline Hcl | Nortriptyline Hcl | 45 | 16 |
| Terazosin Hcl | Terazosin Hcl | 45 | 11 |
| Lovastatin | Lovastatin | 43 | 14 |
| Ondansetron Hcl | Ondansetron Hcl | 41 | 20 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 40 | 14 |
| Ozempic | Semaglutide | 40 | 12 |
| Venlafaxine Hcl | Venlafaxine Hcl | 39 | 14 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 38 | 15 |
| Temazepam | Temazepam | 37 | suppressed |
| Fluconazole | Fluconazole | 36 | 25 |
| Cephalexin | Cephalexin | 35 | 30 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 35 | suppressed |
| Nitroglycerin | Nitroglycerin | 35 | 18 |
| Sumatriptan Succinate | Sumatriptan Succinate | 35 | 14 |
| Finasteride | Finasteride | 34 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 34 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 33 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 32 | 13 |
| Metolazone | Metolazone | 31 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 31 | suppressed |
| Synthroid | Levothyroxine Sodium | 31 | 11 |
| Breyna | Budesonide/Formoterol Fumarate | 30 | suppressed |
| Nystatin | Nystatin | 30 | 13 |
| Aripiprazole | Aripiprazole | 29 | suppressed |
| Folic Acid | Folic Acid | 29 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 29 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 28 | 25 |
| Bupropion Hcl Sr | Bupropion Hcl | 28 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 28 | 13 |
| Nifedipine Er | Nifedipine | 28 | 11 |
| Pregabalin | Pregabalin | 28 | suppressed |
| Topiramate | Topiramate | 28 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 27 | suppressed |
| Levofloxacin | Levofloxacin | 27 | 25 |
| Doxycycline Hyclate | Doxycycline Hyclate | 26 | 11 |
| Primidone | Primidone | 26 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 25 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 25 | 11 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 25 | suppressed |
| Nabumetone | Nabumetone | 25 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 25 | suppressed |
| Mounjaro | Tirzepatide | 24 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 23 | 11 |
| Metronidazole | Metronidazole | 23 | 20 |
| Sildenafil Citrate | Sildenafil Citrate | 23 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 23 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 22 | suppressed |
| Glipizide | Glipizide | 22 | 11 |
| Mupirocin | Mupirocin | 22 | 12 |
| Dilt-Xr | Diltiazem Hcl | 21 | suppressed |
| Naproxen | Naproxen | 21 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 20 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 20 | suppressed |
| Amoxicillin | Amoxicillin | 19 | 18 |
| Oxycodone Hcl | Oxycodone Hcl | 19 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 18 | suppressed |
| Risperidone | Risperidone | 17 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 16 | suppressed |
| Bupropion Xl | Bupropion Hcl | 16 | suppressed |
| Erythromycin | Erythromycin Base | 16 | 12 |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 16 | suppressed |
| Myrbetriq | Mirabegron | 16 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 16 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 16 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 15 | suppressed |
| Dutasteride | Dutasteride | 15 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 15 | suppressed |
| Sucralfate | Sucralfate | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 14 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 14 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 14 | suppressed |
| Irbesartan | Irbesartan | 14 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 14 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 13 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 13 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 12 | suppressed |
| Calcitriol | Calcitriol | 12 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 12 | suppressed |
| Fluphenazine Hcl | Fluphenazine Hcl | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Levemir Flexpen | Insulin Detemir | 12 | suppressed |
| Nystop | Nystatin | 12 | suppressed |
| Pen Needles | Pen Needle, Diabetic | 12 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Famciclovir | Famciclovir | 11 | suppressed |
| Januvia | Sitagliptin Phosphate | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $809.39 · 38 records | GlaxoSmithKline, LLC. | AIRSUPRA, CAPVAXIVE, Cologuard Collection Kit, ELIQUIS, EVENITY, FARXIGA, GEMTESA, JARDIANCE, KISUNLA, Leqembi, NURTEC ODT, OTEZLA, Ozempic, REPATHA, SHINGRIX, TRELEGY ELLIPTA, WATCHMAN Access System, Wegovy | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error